Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing

Published:2019-03-12 Issue: Volume:10 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Dong Jingsi,Li Bingjie,Lin Dan,Zhou Qinghua,Huang Depei

Funder

Department of Science and Technology of Sichuan Province

Health and Family Planning Commission of Sichuan Province

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference81 articles.

1. Epidermal growth factor receptor as a target for cancer therapy.;Altaha;Expert Rev. Anticancer Ther.,2007

2. Entrectinib, a Pan-TRK.;Ardini;Mol. Cancer Ther.,2016

3. Combination osimertinib and gefitinib in C797S and T790M EGFR-mutated non-small cell lung cancer.;Arulananda;J. Thorac. Oncol.,2017

4. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression.;Awad;J. Clin. Oncol.,2016

5. First macrocyclic 3(rd)-generation ALK inhibitor for treatment of ALK/ROS1 cancer: clinical and designing strategy update of lorlatinib.;Basit;Eur. J. Med. Chem.,2017

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision Medicine in Cytopathology;Surgical Pathology Clinics;2024-09

2. Osimertinib treatment response in a patient with lung adenocarcinoma harboring two rare EGFR mutations: A case report;Oncology Letters;2024-08-16

3. A novel mitochondria-related algorithm for predicting the survival outcomes and drug sensitivity of patients with lung adenocarcinoma;Frontiers in Molecular Biosciences;2024-08-08

4. FAM189A2 plays a tumour suppressor role in lung adenocarcinoma by influencing cell apoptosis, CXCR4 expression and tight junction proteins;Tissue and Cell;2024-08

5. TCF19 promotes cell proliferation and tumor formation in lung cancer by activating the Raf/MEK/ERK signaling pathway;Translational Oncology;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3